Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment
Copyright © 2020. Published by Elsevier B.V..
Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis, inflammatory bowel disease (IBD), and noninfectious uveitis form a distinct group among the immune mediated inflammatory diseases. Thus, many patients suffer from more than one of these disease manifestations. Here, we will use the term spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) spectrum disease. The aim is to review the new targeted pharmacological treatment options for all these diseases. All biological or targeted synthetic drugs with U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval for any of the diagnoses axSpA, PsA, psoriasis, IBD, or non-infectious uveitis were included. Some of the drugs have documented efficacy in more than one of the diseases, e.g. tumor necrosis factor (TNF) inhibitors. However, other drugs are particularly effective for a specific inflamed tissue and approved in only one or two of the disease entities, e.g. abatacept for peripheral arthritis and vedolizumab for inflammatory bowel disease. This contributes with bedside to bench understanding of the immunology underlying this disease spectrum and provides clinicians with an overview that can assist stratified treatment decisions. We hope that this review will help guide clinicians to speed up treatment of patients with this disease spectrum.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 20(2021), 2 vom: 01. Feb., Seite 102731 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brüner, Mads [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.02.2021 Date Revised 15.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2020.102731 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318919184 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318919184 | ||
| 003 | DE-627 | ||
| 005 | 20231225170352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2020.102731 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM318919184 | ||
| 035 | |a (NLM)33326852 | ||
| 035 | |a (PII)S1568-9972(20)30312-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brüner, Mads |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2021 | ||
| 500 | |a Date Revised 15.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
| 520 | |a Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis, inflammatory bowel disease (IBD), and noninfectious uveitis form a distinct group among the immune mediated inflammatory diseases. Thus, many patients suffer from more than one of these disease manifestations. Here, we will use the term spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) spectrum disease. The aim is to review the new targeted pharmacological treatment options for all these diseases. All biological or targeted synthetic drugs with U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval for any of the diagnoses axSpA, PsA, psoriasis, IBD, or non-infectious uveitis were included. Some of the drugs have documented efficacy in more than one of the diseases, e.g. tumor necrosis factor (TNF) inhibitors. However, other drugs are particularly effective for a specific inflamed tissue and approved in only one or two of the disease entities, e.g. abatacept for peripheral arthritis and vedolizumab for inflammatory bowel disease. This contributes with bedside to bench understanding of the immunology underlying this disease spectrum and provides clinicians with an overview that can assist stratified treatment decisions. We hope that this review will help guide clinicians to speed up treatment of patients with this disease spectrum | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a Dactylitis | |
| 650 | 4 | |a Enterocolitis | |
| 650 | 4 | |a Enthesitis | |
| 650 | 4 | |a Immune mediated inflammatory disease | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Noninfectious uveitis | |
| 650 | 4 | |a Peripheral synovitis | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Spondylitis | |
| 650 | 4 | |a Spondyloarthritis | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a Uveitis | |
| 700 | 1 | |a Dige, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Loft, Anne Gitte |e verfasserin |4 aut | |
| 700 | 1 | |a Laurberg, Trine Bay |e verfasserin |4 aut | |
| 700 | 1 | |a Agnholt, Jørgen Steen |e verfasserin |4 aut | |
| 700 | 1 | |a Clemmensen, Kåre |e verfasserin |4 aut | |
| 700 | 1 | |a McInnes, Iain |e verfasserin |4 aut | |
| 700 | 1 | |a Lories, Rik |e verfasserin |4 aut | |
| 700 | 1 | |a Iversen, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Hjuler, Kasper Fjellhaugen |e verfasserin |4 aut | |
| 700 | 1 | |a Kragstrup, Tue Wenzel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 20(2021), 2 vom: 01. Feb., Seite 102731 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:2 |g day:01 |g month:02 |g pages:102731 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2020.102731 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 2 |b 01 |c 02 |h 102731 | ||